Latest news with #IntelliSep
Medscape
6 days ago
- Health
- Medscape
Rapid Sepsis Test Boosts ED Discharge Rates
TOPLINE: A rapid host response sepsis test, IntelliSep, when implemented early in triage across emergency departments (EDs), led to a significant increase in discharge rates and hospital-free days. METHODOLOGY: Researchers integrated the IntelliSep host response test into the screening of 4650 patients who presented with signs of infection at four EDs in Louisiana and Mississippi between 2024 and 2025. The test measured leukocyte biophysical properties and generated an index (0.1-10.0) from whole blood within 10 minutes. Patients were stratified into three bands on the basis of the risk for sepsis: band 1 (low risk), band 2 (moderate risk), and band 3 (high risk). Screening was conducted through a nurse-driven triage protocol, followed by a physician-driven protocol, with treatment decisions guided by the test result. Outcomes were ED discharge rates, 30-day return visits, and return-adjusted hospital-free days. TAKEAWAY: Based on the test results, 54.8% of patients were classified as low-risk patients (band 1), 25.7% as intermediate-risk patients (band 2), and 19.6% as high-risk patients (band 3). From month 1 to month 4, ED discharge rates increased by 55.9% in patients with low risk (from 22.0% to 34.3%; P < .01) and by 78% in those with intermediate risk (from 10.5% to 18.7%; P < .05). Median return-adjusted hospital-free days increased by 1 day in the overall cohort (from 26.0 to 27.0 days; P < .0001), with a 1-day increase for low-risk patients (from 27.0 to 28.0 days; P < .0001) and a 2-day increase for high-risk patients (from 25.0 to 27.0 days; P < .05). ED return rates remained unchanged across all risk bands throughout the study period. Mortality rates among low-risk patients declined from 10.6% at month 1 to 6.3% at month 4 (P < .05). IN PRACTICE: "Improving quality of care in the ED required our health system to tackle sepsis — a time-sensitive condition that can be deadly if not addressed quickly. Rapid diagnostics like IntelliSep help our team make better treatment decisions," lead author Christopher Thomas, MD, Vice President and Chief Quality Officer at FMOLHS and critical care physician at LSU Health Sciences Center, said in a press release. "By ruling out sepsis for low-risk patients, we're reducing avoidable admissions and creating bed capacity for critically ill patients," the authors wrote. SOURCE: The study was led by Christopher Thomas, MD, Our Lady of the Lake Regional Medical Center, Baton Rouge, Los Angeles. The study was presented at the 2025 Association for Diagnostics & Laboratory Medicine (ADLM) Clinical Lab Expo. LIMITATIONS: The 4-month rollout limits causal inference and long-term insights. Patients with missing discharge disposition data were excluded from the analysis, which may have affected the completeness of the results. DISCLOSURES: One of the study authors is affiliated with Cytovale Inc, the company that developed the IntelliSep test. The authors did not report any funding sources. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
12-06-2025
- Health
- Yahoo
Cytovale's Rapid Diagnostic Slashes Sepsis Mortality by 39%, Peer-Reviewed Study Confirms
Cytovale's IntelliSep® sepsis test highlights a new model for ED triage that's already delivering systemwide clinical and economic value Results of real-world study with 12,000+ patients published in the journal Healthcare SAN FRANCISCO, June 12, 2025 /PRNewswire/ -- One of the largest real-world studies of a sepsis diagnostic reveals that Cytovale's IntelliSep®, a U.S. Food and Drug Administration (FDA)-cleared rapid host response diagnostic, reduced the relative rate of sepsis mortality by 39%, shortened length of hospital stay and enabled more efficient resource allocation in the emergency department (ED). The study, "Impact of a Sepsis Quality Improvement Initiative on Clinical and Operational Outcomes," published in the peer-reviewed journal Healthcare, followed more than 12,000 patients over 12 months at Our Lady of the Lake Regional Medical Center (OLOLRMC), a 900-bed in-patient acute care facility and Level 1 trauma center in Baton Rouge, La. "This is the kind of data the medical field has been waiting for and the results represent a breakthrough in sepsis care," said Dr. Christopher Thomas, study author who serves as Vice President and Chief Quality Officer at Franciscan Missionaries of Our Lady Health System (FMOLHS) and is a critical care physician at Louisiana State University Health Sciences Center. "With this small operational change, we are able to save more lives, deliver better care faster and optimize use of hospital resources. It's a pivotal step forward in how emergency departments manage sepsis. With IntelliSep, we've discovered a new way to save lives." Key Study Findings 39% relative rate reduction in sepsis mortality, with non-sepsis mortality unchanged, validating the impact of IntelliSep on targeted triage. 0.76 day decrease in average hospital length of stay for sepsis patients, with strong implications for improved throughput and cost reduction. 40% decrease in blood culture usage in low risk patients and an 8% increase in high-risk cases, underscoring the ability of IntelliSep to help providers fine-tune diagnostic precision. Detecting Sepsis in Minutes, Bringing Speed and Confidence to the FrontlineSepsis is one of the most elusive and deadly conditions in modern medicine, responsible for nearly one in three hospital deaths in the United States. EDs often err on the side of caution, treating a wide range of incoming patients as potentially septic because there is a lack of reliable, objective methods for early risk assessment. Treating every patient as potentially septic, while understandable in a high-stakes environment like the ED, often results in unnecessary, non-beneficial interventions for patients who likely do not have sepsis. The strains on limited ED resources was a top concern for OLOLRMC when it implemented IntelliSep as part of a nurse-driven sepsis triage initiative designed to identify and rapidly triage patients at highest risk. IntelliSep is the first and only FDA-cleared diagnostic to aid in early sepsis detection in the ED. Using a routine blood draw, the test delivers results in about eight minutes. This helps clinicians to rule in or rule out sepsis even before clinical signs are fully visible, giving them greater confidence to determine which patients are in most urgent need of care. The combination of a rapid diagnostic and a protocolized workflow has yielded what the study authors describe as a "game-changing model" for health systems nationwide. "This is more than an innovation – it's a paradigm shift in how health systems are managing sepsis," said Dr. Hollis O'Neal, Medical Director of Research at OLOLRMC. "For decades, sepsis mortality rates have remained stagnant because we've lacked a fast, reliable way to catch sepsis early. This study proves that with speed, objectivity and accuracy at the point of triage, we can change outcomes before antibiotics are given or ICU beds are needed. That's where real transformation begins." Validated in One Hospital, Scaled Across the Health SystemSepsis is not just a clinical challenge, it's a financial one. For hospitals with more than 500 beds, annual sepsis-related costs can exceed $34 million. A bet on a new approach to sepsis care paid off for OLOLRMC. Reflecting its confidence in IntelliSep's clinical and operational impact at scale, the system's leadership has expanded IntelliSep across four additional sites within FMOLHS. "As health systems face mounting pressures to deliver efficient, effective care, adopting this precise, rapid method will be key to saving lives and controlling costs," Dr. Thomas added. "Those who embrace this approach position themselves at the forefront of sepsis care innovation." About Cytovale®Cytovale is committed to improving patient care by pioneering early detection technologies that assess immune activation to accelerate the time it takes to get from triage to life-saving therapies. Cytovale's U.S. Food and Drug Administration-cleared rapid sepsis diagnostic, IntelliSep®, leverages machine learning and advanced microfluidics to provide Emergency Department clinicians with an objective and highly sensitive early detection tool for sepsis. IntelliSep measures the dysregulated immune system response to infection that would indicate sepsis and generates results in about eight minutes using a standard blood draw. Cytovale is based in San Francisco and venture-backed by Norwest Venture Partners, Sands Capital and Global Health Investment Corporation (GHIC). For more information, visit and follow Cytovale on LinkedIn and X. View original content to download multimedia: SOURCE Cytovale Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
